@article{2983048,
    title = "Plasma levels of soluble AβPPβ as a biomarker for Alzheimer's disease with dementia",
    author = "Alexopoulos, P. and Thierjung, N. and Economou, P. and Werle, L. and Buhl, F. and Kagerbauer, S. and Papanastasiou, A.D. and Grimmer, T. and Gourzis, P. and Berthele, A. and Hemmer, B. and Kübler, H. and Martin, J. and Politis, A. and Perneczky, R.",
    journal = "Journal of Alzheimer's disease : JAD",
    year = "2019",
    volume = "69",
    number = "1",
    pages = "83-90",
    publisher = "IOS Press BV",
    doi = "10.3233/JAD-181088",
    keywords = "abetappbeta protein;  amyloid beta protein;  apolipoprotein E4;  unclassified drug;  amyloid precursor protein;  biological marker;  tau protein, adult;  aged;  Alzheimer disease;  Article;  cerebrospinal fluid;  cerebrospinal fluid level;  clinical article;  cost effectiveness analysis;  daily life activity;  dementia;  diagnosis related group;  disease marker;  elective surgery;  enzyme linked immunosorbent assay;  female;  genotype;  human;  limit of detection;  male;  Mini Mental State Examination;  peripheral nervous system;  priority journal;  procedures;  protein blood level;  spinal anesthesia;  urologic surgery;  Alzheimer disease;  blood;  dementia;  middle aged, Aged;  Alzheimer Disease;  Amyloid beta-Protein Precursor;  Biomarkers;  Dementia;  Female;  Humans;  Male;  Middle Aged;  tau Proteins",
    abstract = "Cost- and time-effective markers of Alzheimer's disease (AD), reliable and feasible at the population level are urgently needed. Soluble amyloid-β protein precursor β (sAβPPβ) in plasma has attracted scientific attention as a potential AD biomarker candidate. Here we report that plasma sAβPPβ levels in patients with AD dementia and typical for AD cerebrospinal fluid (CSF) biomarker profiles (N=33) are significantly lower (p<0.01) than those of cognitively healthy elderly individuals without AD (N=39), while CSF sAβPPβ levels did not differ between the studied groups. This provides further evidence for the potential of sAβPPβ in plasma as an AD biomarker candidate. © 2019 - IOS Press and the authors. All rights reserved."
}